Nova Junk, a family-owned junk removal company based in Alexandria, Virginia, celebrates two decades of responsible hauling, recycling, and donation services across the Washington DC metro region.
Washington, United States, 16th Jul 2026 – Nova Junk, a locally owned junk removal company serving Washington, DC, Northern Virginia, and Maryland, is marking its 20th year in business. Founded on September 11, 2005, according to information published on the company website, the company has grown from a two-person family operation into a multi-service hauling company with a team that includes extended family members and long-tenured employees.
Nova Junk provides junk removal, estate cleanouts, office cleanouts, construction debris removal, yard debris hauling, shed removal, hot tub disposal, and labor-only services, according to the company website. The company serves communities throughout the Washington DC metro area, including Alexandria, Fairfax, Arlington, Bethesda, Montgomery County, and Prince George County.
A distinguishing feature of Nova Junk’s operating model is its three-stage disposal process: donate, recycle, and landfill. According to information published on the company website, the team sorts through all collected material, first setting aside items that can be donated to local charities and then separating recyclable materials such as batteries, printers, and refrigerators. Only the remainder goes to the landfill, and the company states that it typically sends just one third of collected material to the dump.
The company is licensed and fully insured, according to the company website, and places a strong emphasis on punctuality and transparent pricing. Nova Junk states that final charges are adjusted downward when a load turns out to be smaller than estimated, a policy highlighted repeatedly in customer reviews published on the company website.
“We started this company as a family and grew it the same way – by treating every customer’s home and business the way we would want ours treated,” said Norman Elbekri, Co-founder at Nova Junk. “After 20 years we are still committed to the same values we started with: honest pricing, responsible disposal, and service that people can count on.”
Nova Junk serves both residential and commercial clients. Services extend to de-cluttering and hoarding solutions, moving and foreclosure cleanouts, and demolition site cleanup. The company operates from two locations – 2000 Duke Street in Alexandria, Virginia and Smoketown Road in Woodbridge, Virginia – and can be reached at novajunk.com.
About Nova Junk
Nova Junk is a family-owned junk removal company founded in 2005, serving Washington, DC, Northern Virginia, and Maryland. The company provides residential and commercial hauling, estate cleanouts, construction debris removal, and specialty services including shed and hot tub removal. Nova Junk is committed to responsible disposal through a donate-recycle-landfill approach that minimizes landfill impact. Learn more at https://www.novajunk.com
The post Nova Junk marks 20 years of eco-friendly junk removal in the Washington DC area appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
Jyong Biotech Ltd. (Nasdaq stock code: MENS) (hereinafter referred to as “the Company” or “Jyong Biotech”) is a science-driven biotechnology company dedicated to developing and commercializing innovative plant-based therapies. The Company recently announced that, following an analysis of the clinical efficacy and competitive advantages of its innovative botanical drugs Botreso® and PCP, it has advanced its market access strategy.
As previously announced by the company, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan, while its second core product, PCP, has successfully completed a Phase II clinical trial. Overall clinical data demonstrate that Jyong Biotech’s innovative botanical drugs exhibit significant differentiation advantages compared to currently marketed synthetic chemical drugs.
Overall Safety Profile for Long-Term Use
For middle-aged and elderly males requiring long-term medication, safety is one of the most decisive factors. In clinical trials—Botreso® (Phase III) had a treatment duration of one year, while PCP (Phase II) lasted two years—no drug-related serious adverse events were observed, demonstrating excellent safety and tolerability.
In contrast, currently available chemically synthesized drugs for the treatment of benign prostatic hyperplasia (BPH) are often associated with adverse effects such as postural hypotension, erectile dysfunction, and decreased libido. Regulatory authorities and research institutions have linked certain synthetic alternative medications to significant risks, prompting the U.S. Food and Drug Administration (FDA) to issue a safety advisory regarding advanced prostate cancer and depression in 2011, and to include suicidal ideation in its list of adverse reactions in 2022. Additionally, an independent study conducted in 2021 also established associations between these drugs and cardiac failure.
Management of risks associated with advanced prostate cancer
Large-scale international clinical trials have demonstrated that while certain synthetic drugs used to treat benign prostatic hyperplasia (BPH) can reduce the overall incidence of prostate cancer, they may paradoxically increase the proportion of advanced prostate cancer (Grisson score ≥ 7) when cancer develops, thereby posing significant clinical safety concerns.
The Phase II clinical trial of PCP was a large-scale, long-term study on rare conditions conducted in Taiwan across 20 major hospitals. Over a period of two years, the trial involved 135 urologists (representing more than one-tenth of all urologists in Taiwan) and enrolled a total of 702 participants. It was one of the first global clinical trials specifically targeting prostate cancer prevention using a novel botanical drug conducted in Taiwan. The results demonstrated that PCP exhibited a downward trend in both overall prostate cancer incidence and the risk of advanced-stage prostate cancer, effectively addressing concerns within the medical community regarding the risks associated with existing therapies.
Comprehensive approach of “Treatment + Prevention + Metabolic Management”
Based on the clinical data from the company’s conducted trials, the company believes it is establishing a differentiated product positioning.
• Improvement of lower urinary tract symptoms (LUTS): Effectively alleviates symptoms associated with benign prostatic hyperplasia.
• Prevention of prostate cancer: Demonstrates prophylactic clinical potential.
• Metabolic and cardiovascular protection: Decreased triglyceride levels (P=0.05), significantly reduced total cholesterol and low-density lipoprotein (bad cholesterol) (P<0.05), significantly increased high-density lipoprotein (good cholesterol) (P<0.05), and maintained stable blood glucose levels.
This comprehensive therapy delivers benefits without adversely affecting blood pressure, liver function, or renal function. The company emphasizes that this integrated approach combining treatment, prevention, and metabolic management is exceptionally rare among current prostate medications and holds significant appeal for men aged 40 and above.
Technical Barriers and Competitive Advantages
Due to the inherent complexity and diversity of components in novel botanical drugs, quality control poses greater challenges compared to that of small-molecule chemical drugs. Jianyong Biotechnology asserts that the company has successfully established a comprehensive technical platform, which includes:
• Purification and establishment of reference standards.
• Development and validation of analytical methods.
• Perform the validation analysis and verification process.
The company believes that such comprehensive capabilities create substantial market entry barriers, rendering the products highly difficult to replicate. Furthermore, they effectively mitigate risks associated with competition from counterfeit and substandard products as well as generic drugs, ultimately contributing to an extended period of market monopoly.
The upgraded market positioning and strategic value
As a plant-based new drug protected by global patents, Jyong Biotech believes its market strategy leverages the following key advantages:
• Pricing competitiveness: Its unique metabolic protection profile and safety profile enable it to command higher prices compared to non-patented generic drugs, making it attractive to both out-of-pocket and high-end healthcare markets.
• Authorization potential: The combination of high tolerability, excellent safety profile (no serious adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical collaboration.
• Market scalability: Expanding the product portfolio from treatment-oriented approaches to the fields of preventive medicine and health management.
Globally, over 500 million men aged 50 and above seek treatment for benign prostatic hyperplasia (BPH). In 2020, the global BPH drug market was valued at $4.1 billion and is projected to reach $9.8 billion by 2026. Although the current treatment market generates annual revenues of approximately $6.5 to $7 billion, this figure reflects price reductions due to patent expiration. If calculated based on prices during the patent period, the market potential exceeds $20 billion annually.
“Due to the complex composition of botanical new drugs, they face significant challenges in quality control compared to small-molecule chemical drugs,” stated Chairman Guo of Jianyong Biotechnology. “We have established a robust technical platform that encompasses the purification of reference standards, development and validation of analytical methods, as well as performance validation analyses. This high entry barrier makes counterfeiting difficult to achieve, reduces competition from generic drugs, and helps extend market exclusivity periods.”
Chairman Guo stated: “Botreso® is Taiwan’s first oral botanical drug to obtain an IND approval from the U.S. FDA for Phase III clinical trials (API-1) and has successfully completed all four Phase III clinical trials.”
Jyong Biotech holds multiple invention patents across Asia, the Americas, and the European Union, and has signed letters of intent and investment agreements with several international pharmaceutical companies. The company plans to further expand its strategic, fee-based licensing partnerships to support its global market expansion.
As of today, Botreso® and PCP remain in the investigational new drug candidate stage and have not yet been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on significant progress.
Company Profile: Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company dedicated to the research, development, and commercialization of innovative and differentiated novel drugs (of plant origin), with a primary focus on the treatment of urinary system disorders, initially targeting the markets in the United States, the European Union, and Asia. Since its establishment in 2002, the company has developed comprehensive capabilities encompassing all critical stages of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging robust R&D capabilities and proprietary platforms, the company has developed a portfolio of plant-derived candidate drugs, including its lead plant-based candidate Botreso®, another plant-based candidate drug in clinical development, and several other plant-based candidates in preclinical stages. The company is committed to developing and delivering cutting-edge innovative therapeutics to address customer health needs and strives to become a respected and valuable enterprise.
United States, 16th Jul 2026, – As the global cycling industry gathers in Frankfurt from June 24 to 27, 2026, TARRAN will exhibit at Booth F12 B26, where the company will debut the new L1 Series alongside its flagship model, the T1 Pro. Visitors can experience both models firsthand at the booth.
Following last year’s market launch of the T1 Pro, Tarran is expanding its portfolio, combining engineering precision with the demands of everyday urban riding.
Featured Models
L1 Series: New for 2026
The new model is engineered for practical everyday use. As TARRAN’s first intelligent longtail cargo bike designed for families, its core innovations include the industry-first SyncStand Auto, an electronic kickstand that parks the bike at the push of a button, and an E-Dropper Post that adjusts saddle height instantly.
Paired with Enviolo AUTOMATIQ Pro automatic shifting, fully integrated into TarranOS, the L1 delivers an intuitive, low-effort riding experience. It features a 100 Nm mid-drive motor, a removable 693 Wh battery built with Samsung cells, and a reinforced longtail frame supporting a maximum gross vehicle weight of 215 kg (474 lb).
For rider and passenger safety, the Vision Unit—combining a rear-view camera and mmWave radar—works together with integrated front and rear turn signals to provide 360-degree protection for the whole family. TARRAN continuously improves the L1 through over-the-air updates, supporting long-term product maintenance and ongoing refinement. A firmware update scheduled for late June will add native control for DJI action cameras and an anti-pinch safety function for the electronic kickstand.
T1 Pro
Successfully launched last year, the flagship model continues to demonstrate the brand’s technological strengths. The T1 Pro is equipped with active safety systems that monitor the bike’s surroundings and assist the rider in critical situations.
The T1 Pro features Tarran’s proprietary Dynamic Dualdrive landing gear, which stabilizes the bike while riding and at a standstill, reducing the risk of tipping. It is designed to carry families with two to three children in comfort, while its compact 2.26-meter (7.4 ft) overall length ensures agile handling.
Putting the Riding Experience First
Tarran believes that genuine innovation is best understood through direct experience. While the exhibit offers a closer look at the underlying technical architecture, consumers and e-bike enthusiasts are welcome to test ride both models directly at the TARRAN booth.
Visitors can see for themselves how the intuitive controls and safety features change the riding experience in urban environments.
Global Growth and Dealer Network
Reflecting TARRAN’s continued growth, and with the L1 Series now in series production, the brand’s products are available in more than 100 retail stores worldwide.
Strengthening its global footprint, TARRAN is now formally entering the North American market, actively building a dealer network across the United States and Canada to bring its intelligent, safety-focused cargo bikes to more families.
Expert Dialogue and Consultations
Tarran offers trade journalists and partners the opportunity for individual, in-depth background briefings. On-site experts will be available in the following areas:
Product Development and Technology: Shiyuan, Product Manager.
Strategy and Marketing: Dennis Wang and Larry Hu.
DACH Region Sales: Sebastian Locher and Jiaming Lee.
Benelux Region Sales: Fabian Hard.
Press Contact and Scheduling: To arrange a briefing or a test ride, please contact tarran@laika.berlin.
About TARRAN
Founded in 2023, TARRAN develops human-centered mobility experiences that combine clean energy with intelligent systems, with the goal of accelerating the transition to a more sustainable future.
The team draws on experience from leading technology companies, including DJI, and believes that technology can help solve real-world challenges while making a positive contribution to the world we live in.
TARRAN currently operates across three locations: Dusseldorf, Hong Kong, and Shenzhen. Its research, development, and testing center is located in Shenzhen, while its manufacturing hubs are situated in Europe and Southeast Asia.
The new report, titled “Back to Basics,” examines bitcoin’s fundamentals, the limits of paper exposure, and the data behind the current buying opportunity, paired with 50% off trading fees and no-cost recurring buys.
Onramp, the bitcoin-centric financial services platform built on Multi-Institution Custody, today released Back to Basics, a summer 2026 research report making the case for owning bitcoin directly at one of the most asymmetric moments in the asset’s history. Bitcoin currently trades roughly ~50% below its late-2025 high, the shallowest drawdown on record by bitcoin’s own historical standard, while the S&P 500 sits within ~1% of its all-time high, the Nasdaq within ~4%, and gold within ~24% of its peak. Alongside the report, Onramp is offering 50% off trading fees and no-cost recurring buys for new clients. The report and offers are available here.
The timing reflects a deliberate view on where the current cycle stands. Prior drawdowns reached 93% in 2011, 85% from 2013 to 2015, 83% in 2017 to 2018, and 77% from 2021 to 2022. Each ended in a new all-time high. The current cycle’s ~50% decline is the shallowest in bitcoin’s history, occurring as the Fear & Greed Index sits at 22, in extreme-fear territory, at the time of writing. The report arrives at the moment sentiment is at its worst and the historical data makes the clearest case for accumulation.
Back to Basics is organized in three sections. The first covers ten foundational ideas behind owning bitcoin: why fiat currency is designed to lose value, how a capped supply of 21 million makes bitcoin’s scarcity verifiable rather than promised, and why direct ownership differs meaningfully from holding an instrument that tracks the price. The second examines the full range of bitcoin exposure, from ETF shares and exchange balances to structured products and treasury equities, laying out what holders actually own in each case and where the counterparty risk sits. The third presents the data: where the current drawdown sits relative to prior cycles and the pattern of recoveries that have followed comparable declines.
“We find that a meaningful share of people who consider themselves bitcoin owners actually hold a paper claim against it. You get the price exposure, but not the asset itself,” said Michael Tanguma, Founder and CEO of Onramp. “That’s what Back to Basics is designed to address. Whether you’ve never owned real bitcoin or you’ve been sitting in a wrapper for years, this campaign is the on-ramp to the real thing. There’s no substitute for holding it directly.”
The report makes clear that paper exposure, however convenient, reintroduces the counterparty risk bitcoin was designed to eliminate. A balance at an exchange is the obligation of a platform that may have lent the coins elsewhere. A fund share is a claim on a fund that holds a claim with a custodian. A yield-bearing product passes a borrower’s risk to the holder as a return. A share in a bitcoin-holding company embeds the asset inside a business with its own leverage and dilution. With each step away from the underlying asset, the holder gains convenience and accepts an additional party between themselves and their bitcoin.
“The fundamentals have not changed. The price has,” said Brian Cubellis, Chief Strategy Officer at Onramp. “Back to Basics gives investors the data and the framework to recognize this for what it is, one of the most compelling accumulation windows in bitcoin’s history, and to act on it.”
The campaign also marks the launch of recurring buys on Onramp, a new feature available to every client with no fees that lets investors dollar-cost average into bitcoin automatically on a schedule they set. Alongside it, both new and existing clients get 50% off the fees on every bitcoin buy and sell through September 7, plus free access to the Back to Basics report.
For those looking to do more, the first 100 clients to open an Onramp Bitcoin IRA pay no first- -year-fees. Separately, clients can access Multi-Institution Custody, the 2-of-3 model Onramp pioneered, at a reduced rate of $100 per month.
Back to Basics also marks an expansion of Onramp Media, the company’s editorial arm. The same week the report was released, Onramp debuted Signal vs. Noise, a new weekly show in which four hosts each bring their top stories to the table and the strongest survive, a format built to separate what matters in markets from what merely trends. Alongside the show, Onramp is standing up a dedicated editorial news desk covering money, markets, and the forces reshaping both. The premise mirrors the report itself: strip away the noise, return to the fundamentals, and follow the signal.
The full report and all offers are available here.
About Onramp
Onramp is a financial platform for people who think about wealth in decades. Onramp Finance, its latest offering, unifies cash accounts with Onramp-funded rewards up to 5% through a partnership with Bridge, a spending card with up to 1.5% cash back, low-cost bitcoin brokerage in all 50 states, bitcoin IRAs, and direct gold access in a single account. Onramp pioneered Multi-Institution Custody (MIC), a model that eliminates reliance on any single custodian by distributing security across independent institutions including Onramp, BitGo, Coincover, and Tetra. No single institution can access, move, or lose a client’s bitcoin. Bitcoin held in MIC is insured by Lloyd’s of London. Users can learn more at onrampbitcoin.com.
Nova Junk, a family-owned junk removal company based in Alexandria, Virginia, celebrates two decades of responsible hauling, recycling, and donation services across the Washington DC metro region.
Washington, United States, 16th Jul 2026 – Nova Junk, a locally owned junk removal company serving Washington, DC, Northern Virginia, and Maryland, is marking its 20th year in business. Founded on September 11, 2005, according to information published on the company website, the company has grown from a two-person family operation into a multi-service hauling company with a team that includes extended family members and long-tenured employees.
Nova Junk provides junk removal, estate cleanouts, office cleanouts, construction debris removal, yard debris hauling, shed removal, hot tub disposal, and labor-only services, according to the company website. The company serves communities throughout the Washington DC metro area, including Alexandria, Fairfax, Arlington, Bethesda, Montgomery County, and Prince George County.
A distinguishing feature of Nova Junk’s operating model is its three-stage disposal process: donate, recycle, and landfill. According to information published on the company website, the team sorts through all collected material, first setting aside items that can be donated to local charities and then separating recyclable materials such as batteries, printers, and refrigerators. Only the remainder goes to the landfill, and the company states that it typically sends just one third of collected material to the dump.
The company is licensed and fully insured, according to the company website, and places a strong emphasis on punctuality and transparent pricing. Nova Junk states that final charges are adjusted downward when a load turns out to be smaller than estimated, a policy highlighted repeatedly in customer reviews published on the company website.
“We started this company as a family and grew it the same way – by treating every customer’s home and business the way we would want ours treated,” said Norman Elbekri, Co-founder at Nova Junk. “After 20 years we are still committed to the same values we started with: honest pricing, responsible disposal, and service that people can count on.”
Nova Junk serves both residential and commercial clients. Services extend to de-cluttering and hoarding solutions, moving and foreclosure cleanouts, and demolition site cleanup. The company operates from two locations – 2000 Duke Street in Alexandria, Virginia and Smoketown Road in Woodbridge, Virginia – and can be reached at novajunk.com.
About Nova Junk
Nova Junk is a family-owned junk removal company founded in 2005, serving Washington, DC, Northern Virginia, and Maryland. The company provides residential and commercial hauling, estate cleanouts, construction debris removal, and specialty services including shed and hot tub removal. Nova Junk is committed to responsible disposal through a donate-recycle-landfill approach that minimizes landfill impact. Learn more at https://www.novajunk.com
The post Nova Junk marks 20 years of eco-friendly junk removal in the Washington DC area appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
Jyong Biotech Ltd. (Nasdaq stock code: MENS) (hereinafter referred to as “the Company” or “Jyong Biotech”) is a science-driven biotechnology company dedicated to developing and commercializing innovative plant-based therapies. The Company recently announced that, following an analysis of the clinical efficacy and competitive advantages of its innovative botanical drugs Botreso® and PCP, it has advanced its market access strategy.
As previously announced by the company, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan, while its second core product, PCP, has successfully completed a Phase II clinical trial. Overall clinical data demonstrate that Jyong Biotech’s innovative botanical drugs exhibit significant differentiation advantages compared to currently marketed synthetic chemical drugs.
Overall Safety Profile for Long-Term Use
For middle-aged and elderly males requiring long-term medication, safety is one of the most decisive factors. In clinical trials—Botreso® (Phase III) had a treatment duration of one year, while PCP (Phase II) lasted two years—no drug-related serious adverse events were observed, demonstrating excellent safety and tolerability.
In contrast, currently available chemically synthesized drugs for the treatment of benign prostatic hyperplasia (BPH) are often associated with adverse effects such as postural hypotension, erectile dysfunction, and decreased libido. Regulatory authorities and research institutions have linked certain synthetic alternative medications to significant risks, prompting the U.S. Food and Drug Administration (FDA) to issue a safety advisory regarding advanced prostate cancer and depression in 2011, and to include suicidal ideation in its list of adverse reactions in 2022. Additionally, an independent study conducted in 2021 also established associations between these drugs and cardiac failure.
Management of risks associated with advanced prostate cancer
Large-scale international clinical trials have demonstrated that while certain synthetic drugs used to treat benign prostatic hyperplasia (BPH) can reduce the overall incidence of prostate cancer, they may paradoxically increase the proportion of advanced prostate cancer (Grisson score ≥ 7) when cancer develops, thereby posing significant clinical safety concerns.
The Phase II clinical trial of PCP was a large-scale, long-term study on rare conditions conducted in Taiwan across 20 major hospitals. Over a period of two years, the trial involved 135 urologists (representing more than one-tenth of all urologists in Taiwan) and enrolled a total of 702 participants. It was one of the first global clinical trials specifically targeting prostate cancer prevention using a novel botanical drug conducted in Taiwan. The results demonstrated that PCP exhibited a downward trend in both overall prostate cancer incidence and the risk of advanced-stage prostate cancer, effectively addressing concerns within the medical community regarding the risks associated with existing therapies.
Comprehensive approach of “Treatment + Prevention + Metabolic Management”
Based on the clinical data from the company’s conducted trials, the company believes it is establishing a differentiated product positioning.
• Improvement of lower urinary tract symptoms (LUTS): Effectively alleviates symptoms associated with benign prostatic hyperplasia.
• Prevention of prostate cancer: Demonstrates prophylactic clinical potential.
• Metabolic and cardiovascular protection: Decreased triglyceride levels (P=0.05), significantly reduced total cholesterol and low-density lipoprotein (bad cholesterol) (P<0.05), significantly increased high-density lipoprotein (good cholesterol) (P<0.05), and maintained stable blood glucose levels.
This comprehensive therapy delivers benefits without adversely affecting blood pressure, liver function, or renal function. The company emphasizes that this integrated approach combining treatment, prevention, and metabolic management is exceptionally rare among current prostate medications and holds significant appeal for men aged 40 and above.
Technical Barriers and Competitive Advantages
Due to the inherent complexity and diversity of components in novel botanical drugs, quality control poses greater challenges compared to that of small-molecule chemical drugs. Jianyong Biotechnology asserts that the company has successfully established a comprehensive technical platform, which includes:
• Purification and establishment of reference standards.
• Development and validation of analytical methods.
• Perform the validation analysis and verification process.
The company believes that such comprehensive capabilities create substantial market entry barriers, rendering the products highly difficult to replicate. Furthermore, they effectively mitigate risks associated with competition from counterfeit and substandard products as well as generic drugs, ultimately contributing to an extended period of market monopoly.
The upgraded market positioning and strategic value
As a plant-based new drug protected by global patents, Jyong Biotech believes its market strategy leverages the following key advantages:
• Pricing competitiveness: Its unique metabolic protection profile and safety profile enable it to command higher prices compared to non-patented generic drugs, making it attractive to both out-of-pocket and high-end healthcare markets.
• Authorization potential: The combination of high tolerability, excellent safety profile (no serious adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical collaboration.
• Market scalability: Expanding the product portfolio from treatment-oriented approaches to the fields of preventive medicine and health management.
Globally, over 500 million men aged 50 and above seek treatment for benign prostatic hyperplasia (BPH). In 2020, the global BPH drug market was valued at $4.1 billion and is projected to reach $9.8 billion by 2026. Although the current treatment market generates annual revenues of approximately $6.5 to $7 billion, this figure reflects price reductions due to patent expiration. If calculated based on prices during the patent period, the market potential exceeds $20 billion annually.
“Due to the complex composition of botanical new drugs, they face significant challenges in quality control compared to small-molecule chemical drugs,” stated Chairman Guo of Jianyong Biotechnology. “We have established a robust technical platform that encompasses the purification of reference standards, development and validation of analytical methods, as well as performance validation analyses. This high entry barrier makes counterfeiting difficult to achieve, reduces competition from generic drugs, and helps extend market exclusivity periods.”
Chairman Guo stated: “Botreso® is Taiwan’s first oral botanical drug to obtain an IND approval from the U.S. FDA for Phase III clinical trials (API-1) and has successfully completed all four Phase III clinical trials.”
Jyong Biotech holds multiple invention patents across Asia, the Americas, and the European Union, and has signed letters of intent and investment agreements with several international pharmaceutical companies. The company plans to further expand its strategic, fee-based licensing partnerships to support its global market expansion.
As of today, Botreso® and PCP remain in the investigational new drug candidate stage and have not yet been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on significant progress.
Company Profile: Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company dedicated to the research, development, and commercialization of innovative and differentiated novel drugs (of plant origin), with a primary focus on the treatment of urinary system disorders, initially targeting the markets in the United States, the European Union, and Asia. Since its establishment in 2002, the company has developed comprehensive capabilities encompassing all critical stages of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging robust R&D capabilities and proprietary platforms, the company has developed a portfolio of plant-derived candidate drugs, including its lead plant-based candidate Botreso®, another plant-based candidate drug in clinical development, and several other plant-based candidates in preclinical stages. The company is committed to developing and delivering cutting-edge innovative therapeutics to address customer health needs and strives to become a respected and valuable enterprise.
United States, 16th Jul 2026, – As the global cycling industry gathers in Frankfurt from June 24 to 27, 2026, TARRAN will exhibit at Booth F12 B26, where the company will debut the new L1 Series alongside its flagship model, the T1 Pro. Visitors can experience both models firsthand at the booth.
Following last year’s market launch of the T1 Pro, Tarran is expanding its portfolio, combining engineering precision with the demands of everyday urban riding.
Featured Models
L1 Series: New for 2026
The new model is engineered for practical everyday use. As TARRAN’s first intelligent longtail cargo bike designed for families, its core innovations include the industry-first SyncStand Auto, an electronic kickstand that parks the bike at the push of a button, and an E-Dropper Post that adjusts saddle height instantly.
Paired with Enviolo AUTOMATIQ Pro automatic shifting, fully integrated into TarranOS, the L1 delivers an intuitive, low-effort riding experience. It features a 100 Nm mid-drive motor, a removable 693 Wh battery built with Samsung cells, and a reinforced longtail frame supporting a maximum gross vehicle weight of 215 kg (474 lb).
For rider and passenger safety, the Vision Unit—combining a rear-view camera and mmWave radar—works together with integrated front and rear turn signals to provide 360-degree protection for the whole family. TARRAN continuously improves the L1 through over-the-air updates, supporting long-term product maintenance and ongoing refinement. A firmware update scheduled for late June will add native control for DJI action cameras and an anti-pinch safety function for the electronic kickstand.
T1 Pro
Successfully launched last year, the flagship model continues to demonstrate the brand’s technological strengths. The T1 Pro is equipped with active safety systems that monitor the bike’s surroundings and assist the rider in critical situations.
The T1 Pro features Tarran’s proprietary Dynamic Dualdrive landing gear, which stabilizes the bike while riding and at a standstill, reducing the risk of tipping. It is designed to carry families with two to three children in comfort, while its compact 2.26-meter (7.4 ft) overall length ensures agile handling.
Putting the Riding Experience First
Tarran believes that genuine innovation is best understood through direct experience. While the exhibit offers a closer look at the underlying technical architecture, consumers and e-bike enthusiasts are welcome to test ride both models directly at the TARRAN booth.
Visitors can see for themselves how the intuitive controls and safety features change the riding experience in urban environments.
Global Growth and Dealer Network
Reflecting TARRAN’s continued growth, and with the L1 Series now in series production, the brand’s products are available in more than 100 retail stores worldwide.
Strengthening its global footprint, TARRAN is now formally entering the North American market, actively building a dealer network across the United States and Canada to bring its intelligent, safety-focused cargo bikes to more families.
Expert Dialogue and Consultations
Tarran offers trade journalists and partners the opportunity for individual, in-depth background briefings. On-site experts will be available in the following areas:
Product Development and Technology: Shiyuan, Product Manager.
Strategy and Marketing: Dennis Wang and Larry Hu.
DACH Region Sales: Sebastian Locher and Jiaming Lee.
Benelux Region Sales: Fabian Hard.
Press Contact and Scheduling: To arrange a briefing or a test ride, please contact tarran@laika.berlin.
About TARRAN
Founded in 2023, TARRAN develops human-centered mobility experiences that combine clean energy with intelligent systems, with the goal of accelerating the transition to a more sustainable future.
The team draws on experience from leading technology companies, including DJI, and believes that technology can help solve real-world challenges while making a positive contribution to the world we live in.
TARRAN currently operates across three locations: Dusseldorf, Hong Kong, and Shenzhen. Its research, development, and testing center is located in Shenzhen, while its manufacturing hubs are situated in Europe and Southeast Asia.
The new report, titled “Back to Basics,” examines bitcoin’s fundamentals, the limits of paper exposure, and the data behind the current buying opportunity, paired with 50% off trading fees and no-cost recurring buys.
Onramp, the bitcoin-centric financial services platform built on Multi-Institution Custody, today released Back to Basics, a summer 2026 research report making the case for owning bitcoin directly at one of the most asymmetric moments in the asset’s history. Bitcoin currently trades roughly ~50% below its late-2025 high, the shallowest drawdown on record by bitcoin’s own historical standard, while the S&P 500 sits within ~1% of its all-time high, the Nasdaq within ~4%, and gold within ~24% of its peak. Alongside the report, Onramp is offering 50% off trading fees and no-cost recurring buys for new clients. The report and offers are available here.
The timing reflects a deliberate view on where the current cycle stands. Prior drawdowns reached 93% in 2011, 85% from 2013 to 2015, 83% in 2017 to 2018, and 77% from 2021 to 2022. Each ended in a new all-time high. The current cycle’s ~50% decline is the shallowest in bitcoin’s history, occurring as the Fear & Greed Index sits at 22, in extreme-fear territory, at the time of writing. The report arrives at the moment sentiment is at its worst and the historical data makes the clearest case for accumulation.
Back to Basics is organized in three sections. The first covers ten foundational ideas behind owning bitcoin: why fiat currency is designed to lose value, how a capped supply of 21 million makes bitcoin’s scarcity verifiable rather than promised, and why direct ownership differs meaningfully from holding an instrument that tracks the price. The second examines the full range of bitcoin exposure, from ETF shares and exchange balances to structured products and treasury equities, laying out what holders actually own in each case and where the counterparty risk sits. The third presents the data: where the current drawdown sits relative to prior cycles and the pattern of recoveries that have followed comparable declines.
“We find that a meaningful share of people who consider themselves bitcoin owners actually hold a paper claim against it. You get the price exposure, but not the asset itself,” said Michael Tanguma, Founder and CEO of Onramp. “That’s what Back to Basics is designed to address. Whether you’ve never owned real bitcoin or you’ve been sitting in a wrapper for years, this campaign is the on-ramp to the real thing. There’s no substitute for holding it directly.”
The report makes clear that paper exposure, however convenient, reintroduces the counterparty risk bitcoin was designed to eliminate. A balance at an exchange is the obligation of a platform that may have lent the coins elsewhere. A fund share is a claim on a fund that holds a claim with a custodian. A yield-bearing product passes a borrower’s risk to the holder as a return. A share in a bitcoin-holding company embeds the asset inside a business with its own leverage and dilution. With each step away from the underlying asset, the holder gains convenience and accepts an additional party between themselves and their bitcoin.
“The fundamentals have not changed. The price has,” said Brian Cubellis, Chief Strategy Officer at Onramp. “Back to Basics gives investors the data and the framework to recognize this for what it is, one of the most compelling accumulation windows in bitcoin’s history, and to act on it.”
The campaign also marks the launch of recurring buys on Onramp, a new feature available to every client with no fees that lets investors dollar-cost average into bitcoin automatically on a schedule they set. Alongside it, both new and existing clients get 50% off the fees on every bitcoin buy and sell through September 7, plus free access to the Back to Basics report.
For those looking to do more, the first 100 clients to open an Onramp Bitcoin IRA pay no first- -year-fees. Separately, clients can access Multi-Institution Custody, the 2-of-3 model Onramp pioneered, at a reduced rate of $100 per month.
Back to Basics also marks an expansion of Onramp Media, the company’s editorial arm. The same week the report was released, Onramp debuted Signal vs. Noise, a new weekly show in which four hosts each bring their top stories to the table and the strongest survive, a format built to separate what matters in markets from what merely trends. Alongside the show, Onramp is standing up a dedicated editorial news desk covering money, markets, and the forces reshaping both. The premise mirrors the report itself: strip away the noise, return to the fundamentals, and follow the signal.
The full report and all offers are available here.
About Onramp
Onramp is a financial platform for people who think about wealth in decades. Onramp Finance, its latest offering, unifies cash accounts with Onramp-funded rewards up to 5% through a partnership with Bridge, a spending card with up to 1.5% cash back, low-cost bitcoin brokerage in all 50 states, bitcoin IRAs, and direct gold access in a single account. Onramp pioneered Multi-Institution Custody (MIC), a model that eliminates reliance on any single custodian by distributing security across independent institutions including Onramp, BitGo, Coincover, and Tetra. No single institution can access, move, or lose a client’s bitcoin. Bitcoin held in MIC is insured by Lloyd’s of London. Users can learn more at onrampbitcoin.com.
Kingstown, St. Vincent and the Grenadines, July 16th, 2026, Chainwire
Cryptocurrency exchange Bitunix has launched the Bitunix Card, a Visa-powered payment solution that allows users to spend their funds on everyday purchases, and earn yield on idle balances.
The launch reflects a growing demand for practical crypto products that connect digital assets with everyday spending. Instead of moving funds between multiple platforms, Bitunix users can now manage payments, and earnings from one place.
The Bitunix Card can be used at more than 130 million merchants worldwide that accept Visa payments. Users can pay for everyday services and subscriptions such as Uber, ChatGPT, Amazon, Spotify, and Netflix, while also using the card when traveling internationally. Payments are completed instantly, allowing users to spend their crypto as easily as they would with any traditional payment card. The card offers up to 8% cashback on eligible spending, with rewards capped at 1,000 USDT monthly.
To support everyday payments across different regions, the Bitunix Card is compatible with major digital wallets such as Apple Pay, Google Pay and Paypal, as well as selected regional payment platforms and local payment networks.
Available through the Bitunix web platform as well as its iOS and Android applications, the card is designed to give users more utility for their USDT beyond trading. Through a unified dashboard, users can manage card balances, transfer funds between accounts, track transactions, monitor cashback rewards, and control card settings in one place.
The card applies standard regional network processing fees, while eligible users may offset these costs through cashback rewards, depending on their VIP tier.
In addition, eligible balances held on the card can automatically earn yield, reaching up to 11.6% annually, depending on the asset and applicable conditions.
“The Bitunix Card goes far beyond payments. It unlocks a seamless, high-yield financial ecosystem built for everyday global commerce,” said Bitunix’s Chief Strategy Officer, Steven Gu.
The card comes with no issuance fee and no monthly maintenance fee. To activate the card, users are required to transfer a minimum balance of 100 USDT to their card account. The funds remain fully available for spending and do not represent an activation fee.
Users can apply for the Bitunix Card directly through the Bitunix platform. The card is offered to eligible Bitunix users who have completed the platform’s identity verification process and reside in supported regions.
The launch is part of Bitunix’s broader effort to make cryptocurrency more practical for everyday use. By combining spending and earning features in a single product, Bitunix gives users more ways to put their digital assets to use in everyday life.
For more information about the Bitunix Card and application details, users can visit the official Bitunix Card page.
About Bitunix
Bitunix is a global cryptocurrency derivatives exchange trusted by over 5 million users across more than 150 countries. Guided by its core principle of better liquidity, better trading, the platform is built for traders who expect more, committed to providing Ultra Trust, Ultra Products, and Ultra Experience. Bitunix offers a fast registration process and a user-friendly verification system to ensure safety and compliance. With global standards of protection through Proof of Reserves (POR) and the Bitunix Care Fund, the exchange prioritizes user trust and fund security. Industry-first innovations like Fixed Risk, TradingView-powered chart suite, along with indicator alerts, cloud-synced templates, provide both beginners and advanced traders with a seamless experience. Making Bitunix one of the most dynamic platforms on the market.
First Miss & Mrs Cross Continent gathering brings together 24 contestants from seven nations and an audience of 450 at the Church of Scientology & Community Centre in Ireland
Brussels, Belgium, 16th Jul 2026— Twenty-four contestants representing seven nations brought fashion, cultural traditions and messages of social responsibility to the first edition of the Miss & Mrs Cross Continent pageant, held on 5 July at the Church of Scientology & Community Centre of Dublin, hosted by Diana Stahl and Asia Kuzma.
The multicultural programme welcomed approximately 450 guests for an afternoon organised around the theme of “beauty and purpose.” Alongside the competition itself, contestants and visitors took part in drug-education activities intended to encourage informed choices and community participation in prevention.
The pageant was sponsored by Broccoli Care Ltd. and organised by Miss & Mrs Cross Continent Events Ltd. in collaboration with The Truth About Drugs Ireland. Contestants presented aspects of their national and personal backgrounds through fashion, artistic performances and individual messages concerning leadership, responsibility and positive change.
The Mayor of South Dublin, Councillor Francis Timmons, addressed the audience and spoke about the value of combining cultural inclusion with preventive education.
“Today’s initiative is an important step in bringing communities together while promoting education and prevention,” Mayor Timmons said. “I was particularly impressed to learn that the contestants embraced The Truth About Drugs campaign as part of their preparation for the pageant. Their willingness to learn and help educate others demonstrates how positive leadership can make a real difference in building healthier, stronger communities.”
The participation of contestants from different cultural backgrounds reflected the increasingly diverse character of communities across Dublin. While the pageant provided a platform for personal achievement and creative expression, organisers also incorporated an educational component intended to give the participants a subject of wider social relevance to examine and communicate.
The exhibition also presented the educational booklets, documentary materials and online courses available through The Truth About Drugs programme. The materials are designed for use by individuals, parents, teachers, community organisations and prevention volunteers and are provided without religious content.
Many of the contestants began engaging with the programme before the pageant. Several completed all fourteen online courses, while others studied selected modules covering substances including cannabis, cocaine, synthetic drugs, prescription drugs, alcohol and painkillers.
Their participation formed part of the preparation for the competition rather than a separate presentation added on the day. Organisers said the intention was to encourage contestants to consider how public visibility can be connected with social responsibility and the sharing of factual information.
The Truth About Drugs initiative is conducted internationally by the Foundation for a Drug-Free World and supported by the Church of Scientology and Scientologists. Its educational approach is based on presenting information in accessible language before young people are exposed to pressure to experiment with drugs.
The campaign was inspired by Scientology founder L. Ron Hubbard, who wrote that “the single most destructive element present in our present culture is drugs.” The programme developed from the Church’s longstanding involvement in drug-prevention education and is now used in a range of community, school and voluntary settings.
Rather than relying primarily on warnings, the materials explain the composition and effects of different substances and include accounts from people who experienced addiction. The purpose is to give readers sufficient information to evaluate claims they may encounter from peers, advertising, entertainment or illicit drug sellers.
“Bringing drug education into a multicultural gathering gives the subject a human and constructive setting,” said Ivan Arjona, representative of the Church of Scientology to the European Union, OSCE, Council of Europe and the United Nations.
“The contestants came from different nations and professional and cultural backgrounds, yet they shared a willingness to become better informed and to use their influence responsibly,” Arjona added. “This reflects values that are central to European community life: human dignity, personal responsibility, prevention and cooperation across cultures. Social leadership is not defined only by visibility, but by what a person chooses to communicate and contribute.”
Cultural traditions represented in Dublin
Following the exhibition tours, guests moved to the auditorium for the main pageant programme. The contestants appeared in a series of presentations reflecting their individual interests, abilities and national traditions.
The programme also included performances by Scoil Rince Ní Aogáin, led by Denise Egan, presenting the tradition of Irish dance. The Mudra School of Indian Classical Dance contributed performances drawn from Indian artistic traditions, while dancers from the Indonesian Irish Association presented traditional Indonesian culture.
The combination of Irish, Indian, Indonesian and other international contributions placed cultural exchange at the centre of the afternoon. For members of Dublin’s migrant communities, the gathering offered an opportunity to present traditions maintained within families and community associations while participating in a shared public programme.
The presentations were followed by the announcement of winners in several categories. The principal title of Miss Cross Continent 2026 was awarded to Niveditha Vudayagiri, a software engineer who holds a master’s degree in artificial intelligence.
Fortunate Lindokuhle Masina was named first runner-up, and Yuki Yuliatin was selected as second runner-up.
The backgrounds of the finalists illustrated the pageant’s emphasis on achievement beyond physical appearance. Professional development, education, cultural participation and community involvement were presented as relevant aspects of how contestants understood leadership.
The organisers said the first edition was conceived as a meeting point between the pageant sector and community initiatives. The cooperation with The Truth About Drugs Ireland gave contestants a practical educational subject to study and allowed visitors to examine the materials directly during the exhibition tours.
The Church of Scientology & Community Centre of Dublin opened in 2017 as a religious and community facility serving Scientologists and the wider public. Its premises include an auditorium, meeting rooms, sports and recreational facilities and spaces used by local organisations for educational, cultural and charitable programmes.
The Centre has hosted activities involving neighbourhood associations, cultural communities, voluntary groups, educators and public representatives. Its community work includes support for drug prevention, human-rights education, moral education and volunteer initiatives.
The Church of Scientology was founded by author and humanitarian L. Ron Hubbard. In addition to the religious services provided to their congregations, Churches of Scientology and their members support secular programmes addressing drug prevention, human-rights awareness, community values and disaster response.
The Miss & Mrs Cross Continent programme concluded with participants and guests recognising education, cooperation and informed decision-making as practical elements in reducing the harm associated with drug abuse. The afternoon connected those subjects with cultural expression and the role of individuals who use public platforms to address issues affecting their communities.
About the Church of Scientology in Europe
The Church of Scientology, its missions, groups and members are present throughout the European continent. Its recognition as a charitable and bona fide religion continues to grow, reflecting its established religious presence and its commitment to education, prevention, freedom of religion or belief and community betterment. Through cooperation with civil-society organisations and local communities, Scientologists support initiatives intended to address social concerns through practical information and voluntary service.
Media Contact
Organization: European Office Church of Scientology for Public Affairs and Human Rights
Content Marketing for Independent Musicians in 2026 offers practical strategies, campaign ideas, platform guidance, planning prompts, and promotional tools for artists working without major-label support. Available as a free download.
United States, 16th Jul 2026 — Independent musicians can release a song worldwide, publish a video, sell merchandise, announce a concert, reach listeners through social media, and communicate directly with fans. The challenge is getting all those activities to support one another.
A new guide, Content Marketing for Independent Musicians in 2026: How to Turn Songs, Stories, Videos, and Shows Into a Career People Can Follow, was created to help artists bring their promotional efforts together without adding an unmanageable amount of work.
The complete guide is available as a free download through Gumroad:
Written for independent bands, solo artists, songwriters, managers, publicists, small labels, and music educators, the guide covers the central parts of a modern artist campaign. Topics include websites, social media, Spotify, YouTube, podcasting, email, direct music sales, merchandise, single releases, concert promotion, tour campaigns, content repurposing, search visibility, and AI-assisted planning.
Rather than treating each platform as another separate responsibility, the guide explains how every channel can have a defined role.
An artist website can provide a permanent home for music, videos, photographs, show dates, merchandise, press materials, and contact information. Social media can help listeners become familiar with the artist. Spotify can support discovery and repeat listening. YouTube can serve as a searchable collection of performances, interviews, videos, and other material. Email gives musicians a way to reach supporters without depending entirely on social media algorithms.
When those pieces are connected, fans have an easier time understanding what the artist is doing, what is available, and how they can become more involved.
“Independent artists are constantly told to post more, film more, promote more, and join more platforms,” said writer and editor Rick Mulholland. “The problem is that musicians are rarely shown how those activities should work together. This guide is meant to help artists build a realistic system around the music they are already creating.”
Replacing Random Posting With a Clearer Process
Many independent musicians are balancing promotion with songwriting, recording, rehearsals, employment, family responsibilities, travel, and live performances.
At the same time, they may feel pressure to post daily, create short videos, maintain several social accounts, start a newsletter, update streaming profiles, pitch playlists, sell merchandise, contact the media, and promote every show.
That workload can quickly become difficult to maintain.
Content Marketing for Independent Musicians in 2026 encourages artists to move away from disconnected posting and instead begin with a central story, release, performance, or project.
That material can then be adapted for several uses.
A detailed artist interview may become:
A website article
A podcast episode
A YouTube video
An email newsletter
A media pitch
Several short social videos
A collection of quotations or graphics
A live performance may support:
A concert announcement
A tour campaign
A YouTube upload
A short-form video
A website feature
An email update
A streaming reminder
The guide does not recommend copying and pasting the exact same message across every platform. Instead, it shows artists how to retain the central story while adjusting the length, format, and presentation for each audience.
A Longer Approach to Promoting New Music
One of the guide’s main sections focuses on helping musicians promote a new single beyond release day.
Many independent campaigns place most of their attention on the day a song becomes available. The artist posts the cover artwork, shares a streaming link, receives support from friends, and then moves on within a few days.
That approach gives the music only a small window in which to reach listeners.
The guide recommends treating a release as an extended story.
Before the release, artists may introduce the song through:
Cover artwork
Lyrics
Rehearsal footage
Studio clips
Early demos
Songwriting stories
Production details
Short video teasers
Presave or preorder links
Interviews
Podcast appearances
After the song is released, promotion can continue with:
Live performances
Acoustic versions
Lyric explanations
Recording stories
Production breakdowns
Fan questions
Press coverage
Listener reactions
Connections to earlier songs
Alternate videos or visualizers
The guide’s approach recognizes that a song remains new to anyone who has not heard it. Extending the campaign gives the release more opportunities to reach people without requiring the artist to invent an entirely new subject every day.
Separate Strategies for Concerts and Tours
The guide also distinguishes between promoting one concert and promoting a complete tour.
A show flyer provides useful information, but repeatedly posting the same image does not always give people a reason to attend.
Artists can strengthen a concert campaign by discussing what makes that appearance different. The story may involve:
A special guest
A hometown performance
An unreleased song
A meaningful venue
A release celebration
A rare acoustic set
A supporting artist
Limited merchandise
Tour promotion requires a broader announcement, but each city also needs its own message.
A fan in one location is usually more interested in the nearby date than the entire tour route. The guide recommends supporting the main tour announcement with city-specific videos, venue information, local media outreach, supporting-act introductions, email reminders, radio contacts, travel updates, ticket information, merchandise previews, and post-show recaps.
This approach turns a tour into a collection of local campaigns rather than one graphic shared repeatedly.
Spotify, YouTube, Bandcamp, and Direct Fan Support
Streaming platforms are covered as part of the artist’s larger career, not as the only measure of progress.
The guide includes recommendations for reviewing and updating Spotify profiles before a release. Artists are encouraged to check their biography, profile image, Artist Pick, merchandise, Canvas visuals, concert listings, and release information.
It also discusses Spotify listener data and how artists may use it to identify songs, cities, and promotional efforts that deserve more attention.
Musicians are warned to be cautious with companies promising guaranteed streams, instant growth, or unexplained playlist placement. A large number on a dashboard does not always represent real listeners or meaningful interest.
YouTube is presented as more than a place for official music videos. An artist’s channel can also include:
Live performances
Interviews
Rehearsal footage
Lyric videos
Studio documentaries
Tour diaries
Podcasts
Short-form clips
Song explanations
Direct sales receive significant attention throughout the guide.
Independent artists may offer digital downloads, vinyl records, CDs, cassettes, signed editions, shirts, posters, bundles, memberships, tickets, and other items through their own stores or platforms such as Bandcamp.
The guide does not present streaming and direct purchases as competing choices. Streaming makes music easy to discover and revisit. Direct purchases give fans another way to support the artist and own something connected to the music.
Artists are also encouraged to explain that difference without criticizing listeners who primarily use streaming services.
Using AI Without Losing the Artist’s Voice
Content Marketing for Independent Musicians in 2026 also examines the growing use of artificial intelligence in music promotion.
AI tools can help musicians develop outlines, organize campaign ideas, create checklists, prepare interview questions, compare headlines, plan calendars, edit existing material, and adapt longer content for different platforms.
The guide does not recommend allowing automated tools to replace the artist’s experiences, opinions, humor, or personality.
Strong artist content still depends on details that only the musician can provide.
Those details may include the real story behind a lyric, a problem during recording, a last-minute arrangement change, a memorable concert, a fan conversation, a local reference, a private joke, or an opinion based on years of experience.
AI may help organize those details, but it cannot create the lived experience behind them.
The guide includes detailed prompts designed to help artists begin projects with clearer instructions. Musicians can add information about their genre, audience, goals, songs, schedule, budget, available time, upcoming shows, and current campaign.
What the Free Guide Includes
Content Marketing for Independent Musicians in 2026 includes:
A detailed music content marketing framework
Artist website planning recommendations
Social media content categories
Short-form and long-form video ideas
Podcast planning guidance
Spotify profile and release preparation
Direct-to-fan sales strategies
Single-release campaign structures
Individual concert promotion
City-by-city tour promotion
Content repurposing methods
Search visibility guidance
AI-assisted workflow suggestions
Artist marketing audits
Detailed planning prompts
Frequently asked questions
Recommended tools and equipment
Platform and music-industry resources
Artists do not need to use every section at once. They can begin with the chapter that addresses their immediate need, such as preparing a single, improving a website, planning a concert campaign, updating a Spotify profile, or organizing a tour.
Why the Complete Guide Is Free
Independent musicians already spend money on instruments, recording, rehearsal space, distribution, transportation, website hosting, merchandise, photography, videos, advertising, and live performances.
Even a reasonably priced marketing resource becomes another expense.
Making the guide free allows artists to use the material without deciding whether another purchase fits the budget. It also makes the resource easier to share with bandmates, managers, students, collaborators, and other musicians.
The Gumroad download is the complete guide. It is not a sample, shortened edition, or preview with important chapters removed.
Download the Free Music Marketing Guide
Content Marketing for Independent Musicians in 2026: How to Turn Songs, Stories, Videos, and Shows Into a Career People Can Follow is available now as a free Gumroad download.
Artists can read the guide from beginning to end or use individual sections while planning releases, concerts, tours, videos, websites, and direct-to-fan campaigns.
Rick Mulholland is a writer, editor, and content creator whose work covers independent music, artist marketing, digital publishing, consumer products, travel, jewelry, and online media.
His music marketing resources are designed to help independent artists organize promotion, communicate more clearly, and develop campaigns they can realistically maintain while continuing to write, record, rehearse, and perform.
Guide:Content Marketing for Independent Musicians in 2026: How to Turn Songs, Stories, Videos, and Shows Into a Career People Can Follow
The post Free Music Marketing Guide for Independent Artists With AI Prompts appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
